Lupin's arm gets UK regulator nod for COPD treatment

Global pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva.

This, in turn, will help in treating chronic obstructive pulmonary disease (COPD).

This is the second inhalation product by Lupin Healthcare for the UK market after Luforbec pressurised metered dose inhaler (pMDI).


“We are pleased to have received the approval of Lutio from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in the UK,” said Thierry Volle, President, EMEA, Lupin.